Xintela

Xintela is a Lund-based biotech company developing stem cell therapies (XSTEM) for osteoarthritis and difficult-to-heal wounds, alongside cancer antibodies through subsidiary Targinta. The company's proprietary integrin α10β1 marker technology enables selection and quality assurance of stem cells, and its Phase I/IIa trial in knee osteoarthritis showed lasting, clinically relevant improvements after a single injection. Listed on Nasdaq First North, Xintela produces stem cells in its own GMP-certified facility in Lund and also offers CDMO services.